Bio Galium Phase

Venom Immunotherapy (Maintenance)

• Standard Dose: 100 mcg administered subcutaneously once every 4 to 8 weeks.
• Induction Phase: Dosing begins at very low levels (e.g., 0.01 mcg to 0.1 mcg) and is increased weekly or bi-weekly until the maintenance dose of 100 mcg is reached.

Apis Mellifera is approved for use in children. The dosing schedule for pediatric patients is generally identical to the adult schedule, as the goal is to achieve a protective level of IgG antibodies regardless of body weight.

Renal Impairment

No specific dose adjustments are typically required for renal impairment, though patients should be monitored for systemic reactions.

Hepatic Impairment

No specific dose adjustments are required for hepatic impairment.

Elderly Patients

Elderly patients may be at higher risk for complications if a systemic reaction occurs (e.g., due to pre-existing cardiovascular disease). Healthcare providers may adjust the rate of dose escalation.

Apis Mellifera must be administered by a healthcare professional in a clinical setting equipped to treat anaphylaxis.

• Administration: Subcutaneous injection, usually in the upper arm.
• Observation: Patients must remain in the clinic for at least 30 minutes following the injection to monitor for immediate allergic reactions.
• Storage: Store the lyophilized powder and reconstituted vials in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

If a dose is missed during the induction phase, the healthcare provider may need to repeat the previous dose or even reduce the dose depending on the length of the delay. During maintenance, a delay of more than 2-3 weeks may require a temporary dose reduction to ensure safety.

An overdose of Apis Mellifera (either a dose given too quickly or a higher-than-intended concentration) can lead to severe systemic reactions or anaphylaxis.

• Signs: Hives, swelling, wheezing, low blood pressure, or loss of consciousness.
• Emergency Measures: Immediate administration of epinephrine and supportive care (oxygen, IV fluids, antihistamines).

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

• Local Redness (Erythema): Redness at the injection site that usually resolves within 24 hours.
• Local Swelling (Edema): Small lumps or swelling at the site of injection, which may feel itchy or warm.
• Pruritus: Itching at the injection site.

• Large Local Reactions: Swelling greater than 10 cm in diameter that may last for 48 to 72 hours.
• Fatigue: A general feeling of tiredness following the injection.
• Headache: Mild to moderate tension-type headache.

• Generalized Urticaria: Hives appearing on parts of the body away from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Vasovagal Syncope: Fainting due to a sudden drop in heart rate and blood pressure, often triggered by the injection process itself.

> Warning: Stop taking Apis Mellifera and call your doctor immediately if you experience any of these.

• Anaphylaxis: A life-threatening allergic reaction characterized by difficulty breathing, throat tightness, and rapid pulse.
• Hypotension: A dangerous drop in blood pressure leading to dizziness or fainting.
• Bronchospasm: Sudden constriction of the muscles in the walls of the bronchioles, causing severe wheezing.

Long-term use in immunotherapy is generally well-tolerated. Some patients may develop persistent nodules at the injection site, though this is rare with standardized extracts.

WARNING: RISK OF SEVERE ALLERGIC REACTIONS

Apis Mellifera can cause severe, life-threatening systemic allergic reactions, including anaphylaxis. This medication should only be administered by healthcare professionals experienced in the treatment of life-threatening allergic reactions. Patients must be observed for at least 30 minutes after administration. This product may not be suitable for patients with severe or unstable asthma or those taking certain medications like beta-blockers.

Report any unusual symptoms to your healthcare provider.

Apis Mellifera is a potent biological extract. It is intended only for patients with a clear clinical history of honey bee allergy and a positive skin or blood test. It should never be self-administered.

According to the FDA-approved labeling, Apis Mellifera carries a boxed warning regarding the risk of severe systemic allergic reactions. Anaphylaxis may occur within minutes of administration. Emergency equipment, including epinephrine and airway management tools, must be immediately available.

• Allergic Reactions / Anaphylaxis Risk: The primary risk is an induced systemic reaction. Patients with high levels of sensitivity require slower dose escalation.
• Asthma: Patients with unstable or severe asthma are at a significantly higher risk for severe bronchospasm during immunotherapy.
• Cardiovascular Disease: Patients with pre-existing heart conditions may be less able to tolerate the physiological stress of a systemic reaction or the effects of epinephrine used to treat it.

• Observation Period: A minimum 30-minute post-injection wait time is mandatory.
• Lung Function: For asthmatic patients, peak flow or spirometry may be checked before administration.
• Skin Testing: Periodic re-evaluation of skin sensitivity may be conducted by your allergist.

Apis Mellifera generally does not affect the ability to drive. However, if a patient experiences dizziness or a vasovagal reaction after the injection, they should wait until symptoms resolve before operating machinery.

Alcohol consumption should be avoided on the day of the injection, as alcohol can increase blood flow to the skin and potentially accelerate the absorption of the allergen, increasing the risk of a reaction.

Immunotherapy is typically continued for 3 to 5 years. Stopping treatment prematurely may result in a loss of the protective effect, leaving the patient at risk for anaphylaxis from future bee stings.

> Important: Discuss all your medical conditions with your healthcare provider before starting Apis Mellifera.

• Beta-Blockers (e.g., Propranolol, Atenolol): These medications can make allergic reactions more severe and, more importantly, can block the effects of epinephrine (adrenaline), which is the primary treatment for anaphylaxis. This combination can be life-threatening.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): Some studies suggest that patients taking ACE inhibitors may have a higher risk of more severe systemic reactions during venom immunotherapy.
• MAO Inhibitors: These may potentiate the effect of epinephrine if it needs to be administered for a reaction.

• Tricyclic Antidepressants: Similar to MAOIs, these can interfere with the body's response to emergency medications used during a reaction.

• Heavy Meals: It is generally recommended to avoid very heavy meals immediately before or after an injection to minimize gastrointestinal distress if a systemic reaction occurs.

• St. John's Wort: May theoretically affect the metabolism of medications used to treat reactions, though clinical data is limited.
• Ephedra/Ma Huang: May increase the risk of cardiovascular side effects if emergency epinephrine is required.

Apis Mellifera administration will lead to an increase in venom-specific IgG antibodies and a transient increase in venom-specific IgE. This is an expected pharmacological effect and not a "false" result.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe Unstable Asthma: Patients with poorly controlled asthma are at an unacceptably high risk of fatal bronchospasm during a reaction.
• Recent Myocardial Infarction: Patients who have had a heart attack within the last 3-6 months may not tolerate the stress of a systemic reaction.
• Known Hypersensitivity to Diluent Components: Such as phenol or human serum albumin used in the preparation.

• Autoimmune Diseases: Use with caution, as immunotherapy may theoretically exacerbate certain autoimmune conditions.
• Malignancy: Patients with active cancer may have altered immune responses.
• Beta-Blocker Therapy: While often considered an absolute contraindication, some specialists may perform a risk-benefit analysis if no alternative heart medication is available.

There is some cross-reactivity between honey bee venom and other Hymenoptera (like bumblebee venom), but there is minimal cross-reactivity with Vespids (yellow jackets, hornets, wasps). Testing is required for each specific venom.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Apis Mellifera.

FDA Pregnancy Category C. Venom immunotherapy is generally not initiated during pregnancy due to the risk of maternal anaphylaxis, which can cause fetal hypoxia. However, if a patient is already on a stable maintenance dose and becomes pregnant, the treatment is usually continued as the risk of a reaction from a natural sting is considered greater than the risk of maintenance injections.

It is not known whether the components of Apis Mellifera pass into breast milk. However, since the proteins are digested in the infant's gut, the risk to the nursing infant is considered negligible. Maintenance therapy is generally considered safe during breastfeeding.

Apis Mellifera is approved for children. Studies have shown that VIT is highly effective in the pediatric population, often providing long-lasting protection even after the treatment is discontinued.

Patients over 65 may have a higher prevalence of cardiovascular disease, making them more vulnerable to the side effects of epinephrine. Dose escalation may be performed more conservatively.

No specific GFR-based adjustments are documented, as the drug is a biological protein extract primarily processed by the immune system and local proteases.

No adjustments are required for patients with liver disease.

> Important: Special populations require individualized medical assessment.

Apis Mellifera extract works by inducing immunological tolerance. It stimulates the production of T-regulatory cells, which secrete IL-10 and TGF-beta. These cytokines suppress the allergic Th2 response and promote the class-switching of B-cells to produce IgG4. This "blocking antibody" prevents the allergen from binding to IgE on mast cells, effectively raising the threshold for an allergic reaction.

The primary pharmacodynamic effect is the reduction of skin reactivity and systemic sensitivity to honey bee venom. The onset of protection begins during the build-up phase, but full protection is typically achieved only after reaching the maintenance dose of 100 mcg. The duration of effect can last for years after a 5-year course of treatment.

| Parameter | Value |

|---|---|

| Bioavailability | High (Local/Subcutaneous) |

| Protein Binding | Variable (Immune Complex Formation) |

| Half-life | Minutes (Peptides) to Hours (Enzymes) |

| Tmax | 1-2 hours (Systemic absorption of components) |

| Metabolism | Proteolysis by endogenous enzymes |

| Excretion | Renal (Small peptide fragments) |

Apis Mellifera extract is a mixture of proteins, peptides, and biogenic amines. The primary allergen is Phospholipase A2 (MW ~14,500 Da). Other major components include Melittin (a 26-amino acid peptide) and Hyaluronidase. The extract is soluble in aqueous diluents containing human serum albumin and phenol.

Apis Mellifera is a Standardized Insect Venom Allergenic Extract. It is related to other venom extracts such as Vespula species (Yellow Jacket) and Polistes species (Wasp) extracts.